On Jan. 29, the FDA announced a revision to the Paxlovid EUA, stating that Paxlovid manufactured and labeled as EUA-labeled Paxlovid currently in U.S. distribution will remain authorized for use through the labeled or extended expiration date, as applicable, or through March 8, whichever is earlier. Pharmacies should visit Pfizer’s website for information on lots of EUA-labeled Paxlovid that are the subject of a shelf-life extension. Take steps today to ensure your pharmacy does not dispense EUA-labeled Paxlovid after the labeled or extended expiration date, or March 8, whichever is earlier. EUA-labeled Paxlovid will no longer be authorized for emergency use after March 8, regardless of the labeled or extended expiration date. However, the Paxlovid EUA will continue to authorize emergency use of Paxlovid manufactured and labeled in accordance with the NDA (NDA-labeled Paxlovid) for the treatment of mild-to-moderate COVID-19 in pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death. Pfizer has information online about programs to help patients afford their prescription for those with commercial insurance or with Medicare, Medicaid or no insurance.
NCPA
